Cargando…
Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib
| Autores principales: | , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967060/ http://dx.doi.org/10.1038/sj.bjc.6605887 |
| _version_ | 1782189636442914816 |
|---|---|
| author | Mickisch, G H J Escudier, B Walzer, S Nuijten, M |
| author_facet | Mickisch, G H J Escudier, B Walzer, S Nuijten, M |
| author_sort | Mickisch, G H J |
| collection | PubMed |
| description | |
| format | Text |
| id | pubmed-2967060 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2010 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-29670602010-11-15 Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib Mickisch, G H J Escudier, B Walzer, S Nuijten, M Br J Cancer Letter to the Editor Nature Publishing Group 2010-10-12 2010-10-12 /pmc/articles/PMC2967060/ http://dx.doi.org/10.1038/sj.bjc.6605887 Text en Copyright © 2010 Cancer Research UK https://creativecommons.org/licenses/by-nc-sa/3.0/This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
| spellingShingle | Letter to the Editor Mickisch, G H J Escudier, B Walzer, S Nuijten, M Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib |
| title | Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib |
| title_full | Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib |
| title_fullStr | Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib |
| title_full_unstemmed | Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib |
| title_short | Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib |
| title_sort | reply: costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967060/ http://dx.doi.org/10.1038/sj.bjc.6605887 |
| work_keys_str_mv | AT mickischghj replycostsofmanagingadverseeventsinthetreatmentoffirstlinemetastaticrenalcellcarcinomabevacizumabincombinationwithinterferona2acomparedwithsunitinib AT escudierb replycostsofmanagingadverseeventsinthetreatmentoffirstlinemetastaticrenalcellcarcinomabevacizumabincombinationwithinterferona2acomparedwithsunitinib AT walzers replycostsofmanagingadverseeventsinthetreatmentoffirstlinemetastaticrenalcellcarcinomabevacizumabincombinationwithinterferona2acomparedwithsunitinib AT nuijtenm replycostsofmanagingadverseeventsinthetreatmentoffirstlinemetastaticrenalcellcarcinomabevacizumabincombinationwithinterferona2acomparedwithsunitinib |